Goldman Sachs analyst Salveen Richter upgraded Adaptive Biotechnologies (ADPT) to Buy from Neutral with a $9 price target Since October 2024, ...

Salveen Richter, Goldman Sachs lead US biotech analyst for global investment research, joins Market Domination with Josh Lipton and Julie Hyman to discuss the impact of tariffs on the biotech sector.

Salveen Richter; Analyst; Goldman Sachs Group, Inc. Yigal Nochomovitz; Analyst; Citigroup Inc. Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Apellis ...

Goldman Sachs analyst Salveen Richter initiated coverage of the company’s stock with a “Buy” rating and a price objective of $42. As per the analyst, Summit Therapeutics Inc. (NASDAQ ...

Goldman Sachs analyst Salveen Richter initiated coverage of the company’s stock with a “Buy” rating and a price objective of $42. As per the analyst, Summit Therapeutics Inc. (NASDAQ ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...

Adaptive Biotechnologies Corporation ADPT gained 7.5% to $8.33. Goldman Sachs analyst Salveen Richter upgraded Adaptive ...

Allogene Therapeutics reported a narrower-than-expected loss for Q4 2024, with an EPS of -$0.28, surpassing the forecast of -$0.32. The company’s stock responded positively, rising 3.66% in ...

Analysts' ratings for Adaptive Biotechnologies (NASDAQ:ADPT) over the last quarter vary from bullish to bearish, as provided by 4 analysts. Summarizing their recent assessments, the table below ...